Navigation Links
Savient Closes Sale of $230 Million in Convertible Senior Notes

EAST BRUNSWICK, N.J., Feb. 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes").  The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments.

The Notes are convertible, under certain circumstances and during certain periods, based on an initial conversion rate of 86.6739 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $11.54 per share of common stock, subject to adjustment in certain circumstances.  The initial conversion price represents a conversion premium of 25% over the last reported sale price of the common stock of $9.23 per share on January 31, 2011.  Upon conversion, the Notes may be settled, at Savient's election, in cash, shares of Savient's common stock or a combination of cash and shares of Savient's common stock.  Savient may redeem some or all of the Notes for cash under certain circumstances on or after February 1, 2015.  The Notes will bear interest at a rate of 4.75% per year.

J.P. Morgan Securities LLC acted as sole book-running manager of the offering.  Lazard Capital Markets LLC and Cowen and Company, LLC acted as co-managers of the offering.  

Savient has filed a registration statement (including a prospectus) with the SEC for the securities offering described in this communication.  Before you invest, you should read the prospectus in that registration statement and other documents Savient has filed with the SEC for more complete information about Savient and this offering. You may obtain these documents free of charge by visiting EDGAR on the SEC Web site at  Alternatively, copies of the prospectus meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; Telephone (631) 254-1735.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy.

Safe Harbor Statement

This press release contains forward-looking statements, including statements about future business prospects, KRYSTEXXA™ and the offering, that are intended to be covered by the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934.  Any statements that are not statements of historical fact (including statements containing the words "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," and "would," and similar expressions) should be considered to be forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated in any forward-looking statements made by Savient, including the factors described in Savient's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which has been filed with the Securities and Exchange Commission.


SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):